Larissa University Hospital
uhl.grTotal trials
41
Active
8
Phase 3
1
Total enrollment
3,884
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Adjuvant Chemotherapy | — | — | — | — | — | 1 | |
| Consolidation Chemotherapy | — | — | — | — | — | 1 |
Next readouts
- 2026-08-30
Top conditions
- Postoperative Pain4
- Surgery4
- Shoulder Surgery3
- Autonomic Nervous System3
- Beach Chair Position2
- Interscalene Block2
- HRV2
- SARS-CoV2 Infection2
Frequently asked questions about Larissa University Hospital
- How many clinical trials does Larissa University Hospital have on ClinicalTrials.gov?
- Larissa University Hospital is listed as the lead sponsor on 41 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Larissa University Hospital's trials are in Phase 3?
- 1 of Larissa University Hospital's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Larissa University Hospital focus on?
- Larissa University Hospital's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Surgery, Shoulder Surgery, Autonomic Nervous System, Beach Chair Position.
- When are Larissa University Hospital's next clinical trial readouts?
- Larissa University Hospital has 1 upcoming primary-completion readout tracked here; the soonest is “Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial”, expected around 2026-08-30.